SYNJARDY

Peak

empagliflozin and metformin hydrochloride

Boehringer Ingelheim

NDAORALTABLET

Approved

Aug 2015

Lifecycle

Peak

Competitive Pressure

0/100

Clinical Trials

Mechanism of Action

Sodium-Glucose Transporter 2 Inhibitors

Pharmacologic Class:

Sodium-Glucose Cotransporter 2 Inhibitor

Clinical Trials (4)

NCT06823856Phase 1Completed

Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 12.5 mg/1000 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy 12.5 mg/1000 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)

Started May 2025

64 enrolled

Diabetes Mellitus Type 2

NCT06792968Phase 1Completed

Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/1000 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy 5 mg/1000 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)

Started Mar 2025

64 enrolled

Diabetes Mellitus Type 2

NCT06766500Phase 1Completed

Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/850 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy® 5 mg/850 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)

Started Jan 2025

64 enrolled

Diabetes Mellitus Type 2

NCT05132023Phase 1Completed

Bioequivalence Study of Empagliflozin & Metformin HCL From Empagliform 12.5/1000 mg F.C.T (Hikma Pharma, Egypt) and Synjardy 12.5/1000 mg F.C.T (Boehringer Ingelheim International GmbH, Germany)

Started Mar 2019

26 enrolled

Healthy